Non-Hormonal Male Contraception
YCT-529 (Retinoic-Acid/RAR-alpha), EPPIN, and Sperm-Specific Targets
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Investigational/preclinical; YCT-529 in early human trials, others preclinical. None FDA-approved (2026)
Reference only. Not medical advice.
What can go wrong
Human safety data are minimal (YCT-529) to nonexistent (most others). Theoretical concerns include effects on vitamin-A-dependent tissues for RAR-alpha inhibitors, and the general uncertainty of first-in-human dosing. Reversibility is demonstrated mainly in animals. No non-hormonal candidate has shown contraceptive efficacy in humans.
This is something to take to a clinician. The Atlas can tell you what is known about non-hormonal male contraception in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Non-hormonal approaches aim to block sperm production or function without touching the hormonal axis - avoiding mood, libido, and lipid effects. The lead candidate, YCT-529 (developed from academic work and advanced by YourChoice Therapeutics), is an oral inhibitor of retinoic acid receptor alpha (RAR-alpha), a pathway essential for sperm cell production; it entered first-in-human trials around 2023-2024. Other targets include EPPIN (a sperm surface protein governing motility) and various sperm-specific enzymes/ion channels. Most of these remain preclinical with promising animal data but limited or no human efficacy evidence.
Skip the hormones: block sperm at a sperm-specific switch and leave testosterone alone.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
YCT-529 blocks RAR-alpha, interrupting the retinoic-acid (vitamin A) signaling that spermatogonia require to differentiate, thereby halting sperm production without altering testosterone or gonadotropins. EPPIN-based approaches target a protein on the sperm surface that, when bound, immobilizes sperm - aiming to disable existing sperm rather than stop production. Other candidates inhibit sperm-specific enzymes (e.g., serine/threonine kinases) or ion channels essential for motility and fertilization, exploiting proteins found only in sperm to limit off-target effects.
The reversibility promise - and the evidence gap
Non-hormonal candidates are marketed by their developers as cleaner: leaving testosterone untouched should avoid mood, libido, and metabolic effects. In mice, oral RAR-alpha inhibition produced reversible infertility with quick recovery after stopping. But mouse efficacy has historically translated poorly to humans in this field, and human data for YCT-529 are early (safety-focused Phase 1). EPPIN and most sperm-specific targets have not reached efficacy trials at all. The hormone-free pitch is biologically appealing but, as of 2026, largely unproven in people.
What it does to fertility
Goal is reversible suppression of sperm production (YCT-529) or sperm function (EPPIN). Animal studies report restored fertility after discontinuation; human reversibility is not yet established.
What people get wrong
Often saidA non-hormonal male pill is available now
ActuallyYCT-529 is in early human safety trials and others are preclinical; none is approved or proven effective in people as of 2026.
Often saidNon-hormonal means side-effect-free
ActuallyIt avoids hormonal side effects in theory, but human safety is barely characterized; 'no hormones' does not equal 'no risk.'
Often saidIt worked in mice, so it'll work in men
ActuallyMale-contraception history is littered with compounds that succeeded in rodents and failed or stalled in humans; translation is the hard part.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- YCT-529 target
- Retinoic acid receptor alpha (RAR-alpha) - blocks vitamin-A signaling needed for sperm production
- YCT-529 developer
- YourChoice Therapeutics (from academic research)
- YCT-529 stage
- Entered first-in-human (Phase 1) trials ~2023-2024
- Other targets
- EPPIN (motility), sperm-specific ion channels/enzymes - mostly preclinical
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Non-Hormonal Male Contraception. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Noman et al. / academic RAR-alpha inhibitor work, mouse studies2023
Oral RAR-alpha inhibition induced reversible infertility in male mice with high efficacy and recovery after withdrawal, supporting YCT-529 development
YourChoice Therapeutics YCT-529 Phase 12023-2024
First-in-human safety trial of a non-hormonal oral male contraceptive candidate began - among the first non-hormonal compounds to reach human testing
O'Rand et al., EPPIN immunocontraception, primate work2004-2011
EPPIN targeting reversibly suppressed sperm motility/fertility in male non-human primates, validating a sperm-surface contraceptive target (preclinical)